OncoTargets and Therapy
Volume 11, 2018 - Issue
Open access
97
Views
24
CrossRef citations to date
0
Altmetric
Original Research
Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
Claudia De Lorenzo1 Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy;2 Ceinge, Biotecnologie Avanzate s.c.a.r.l., Naples, ItalyCorrespondence[email protected]
, Rolando Paciello1 Department of Molecular Medicine and Medical Biotechnology, University of Naples “Federico II”, Naples, Italy;2 Ceinge, Biotecnologie Avanzate s.c.a.r.l., Naples, Italy
, Gennaro Riccio3 Department of Pharmacy, Federico II University, Naples, Italy
, Domenica Rea4 Division of Cardiology, Istituto Nazionale Tumori – Irccs Fondazione G. Pascale, Naples, Italy
, Antonio Barbieri4 Division of Cardiology, Istituto Nazionale Tumori – Irccs Fondazione G. Pascale, Naples, Italy
, Carmela Coppola4 Division of Cardiology, Istituto Nazionale Tumori – Irccs Fondazione G. Pascale, Naples, Italy
& Nicola Maurea4 Division of Cardiology, Istituto Nazionale Tumori – Irccs Fondazione G. Pascale, Naples, ItalyCorrespondence[email protected]
show all
Pages 2241-2250
|
Published online: 19 Apr 2018
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.